Cargando…

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?

BACKGROUND: Rifamycins are a group of antibiotics mainly used in the treatment of tuberculosis (TB), however they interact with antiretroviral therapy (ART). Rifabutin allows more regimens options for concomitant imunodeficiency virus (HIV) treatment compared to rifampicin. OBJECTIVE: Compare the ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmaltz, Carolina Arana Stanis, Demitto, Fernanda de Oliveira, Sant’Anna, Flavia Marinho, Rolla, Valeria Cavalcanti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372173/ https://www.ncbi.nlm.nih.gov/pubmed/30758392 http://dx.doi.org/10.1590/0074-02760180420

Ejemplares similares

Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil
por: Mann, Danielle, et al.
Publicado: (2018)

Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV
por: Demitto, Fernanda O., et al.
Publicado: (2020)

Anemia in tuberculosis cases: A biomarker of severity?
por: de Mendonça, Edson Beyker, et al.
Publicado: (2021)

Correction: Anemia in tuberculosis cases: A biomarker of severity?
por: de Mendonça, Edson Beyker, et al.
Publicado: (2021)

Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014
por: Cardoso, Mayara A., et al.
Publicado: (2017)

Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil
por: Demitto, Fernanda O., et al.
Publicado: (2019)

Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2012)

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial
por: Xavier, Mariana S., et al.
Publicado: (2018)

Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients
por: da Silva, Tatiana Pereira, et al.
Publicado: (2017)

Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia
por: Sarkar, Trina, et al.
Publicado: (2020)

Changes in the NK Cell Repertoire Related to Initiation of TB Treatment and Onset of Immune Reconstitution Inflammatory Syndrome in TB/HIV Co-infected Patients in Rio de Janeiro, Brazil—ANRS 12274
por: Giacoia-Gripp, Carmem Beatriz Wagner, et al.
Publicado: (2019)

Impact of adverse drug reactions on the outcomes of tuberculosis treatment
por: Sant´Anna, Flávia M., et al.
Publicado: (2023)

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens
por: da Silva, Tatiana P., et al.
Publicado: (2013)

Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients
por: Lehloenya, Rannakoe J., et al.
Publicado: (2016)

Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency
por: Anthony, Richard M, et al.
Publicado: (2005)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Comprehensive in vitro analysis evaluating the variable drug–drug interaction risk of rifampicin compared to rifabutin
por: Nilles, Julie, et al.
Publicado: (2023)

In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis
por: Demitto, Fernanda de Oliveira, et al.
Publicado: (2015)

Correction: In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis
por: Demitto, Fernanda de Oliveira, et al.
Publicado: (2015)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2015)

Global access of rifabutin for the treatment of tuberculosis – why should we prioritize this?
por: Rockwood, Neesha, et al.
Publicado: (2019)

Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study
por: Araújo-Pereira, Mariana, et al.
Publicado: (2023)

Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
por: Kouanda, Seni, et al.
Publicado: (2020)

Danger in the streets: exposures to bloodborne pathogens after community sharp injuries in Rio de Janeiro, Brazil
por: Costa, Marcellus Dias, et al.
Publicado: (2017)

Comparative analysis of the drug-drug interaction between immunosuppressants, safety and efficacy of rifabutin from rifampicin-based Anti-TB treatment in living donor liver transplant recipients with active tuberculosis
por: Wang, Yu-Chen, et al.
Publicado: (2021)

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis
por: Kim, Manse, et al.
Publicado: (2022)

Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy
por: Tanuma, Junko, et al.
Publicado: (2013)

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
por: Jing, Wei, et al.
Publicado: (2017)

rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis
por: Li, Ma-Chao, et al.
Publicado: (2022)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
por: Borraccino, Antonia Valeria, et al.
Publicado: (2022)

Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis
por: Spies, Ruan, et al.
Publicado: (2022)

Rifabutin Is Active against Mycobacterium abscessus Complex
por: Aziz, Dinah Binte, et al.
Publicado: (2017)

Rifabutin Is Active against Mycobacterium abscessus in Mice
por: Dick, Thomas, et al.
Publicado: (2020)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
por: Sharma, Sandeep, et al.
Publicado: (2017)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2n7e813m17ht798bs530vj6u1c